Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ee Chee Ren

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
BMC Infectious Diseases|September 11, 2004
A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infectionLisa F P Ng, Martin L Hibberd, Eng-Eong Ooi, et al.
Allergy|September 3, 2022
In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90α-NOD2-NLRP3 nexusHui Ling Ko, Nicole Zhuo, Zi Wei Chang, et al.
Journal of Clinical Microbiology|January 13, 2004
Detection of severe acute respiratory syndrome coronavirus in blood of infected patientsLisa F P Ng, Michelle Wong, Susie Koh, et al.
Trials|June 16, 2022
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]Xuan Ying Poh, I Russel Lee, Clarissa Lim, et al.
Pharmacogenomics|June 9, 2017
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approachWei Chuen Tan-Koi, Cynthia Sung, Yong Yeow Chong, et al.
Frontiers in Immunology|December 1, 2022
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individualsYun Shan Goh, Angeline Rouers, Siew-Wai Fong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical TrialXuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Journal of Medical Virology|October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boostersAngeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
BMC Infectious Diseases|September 11, 2004
A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infectionLisa F P Ng, Martin L Hibberd, Eng-Eong Ooi, et al.
Allergy|September 3, 2022
In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90α-NOD2-NLRP3 nexusHui Ling Ko, Nicole Zhuo, Zi Wei Chang, et al.
Journal of Clinical Microbiology|January 13, 2004
Detection of severe acute respiratory syndrome coronavirus in blood of infected patientsLisa F P Ng, Michelle Wong, Susie Koh, et al.
Trials|June 16, 2022
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]Xuan Ying Poh, I Russel Lee, Clarissa Lim, et al.
Pharmacogenomics|June 9, 2017
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approachWei Chuen Tan-Koi, Cynthia Sung, Yong Yeow Chong, et al.
Frontiers in Immunology|December 1, 2022
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individualsYun Shan Goh, Angeline Rouers, Siew-Wai Fong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical TrialXuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Journal of Medical Virology|October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boostersAngeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Pageof 7